Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$46.21 – $58.16
68% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $33.53B | $35.41B | $36.28B | $37.52B | $40.84B | $22.30B | $21.83B | $22.86B |
| Cost of revenue | $23.70B | $25.06B | $25.96B | $27.21B | $30.11B | $17.24B | $16.45B | $17.17B |
| Gross profit | $9.83B | $10.35B | $10.32B | $10.31B | $10.72B | $5.06B | $5.38B | $5.69B |
| Gross margin | 29.3% | 29.2% | 28.4% | 27.5% | 26.3% | 22.7% | 24.6% | 24.9% |
| R&D | $673.0M | $645.0M | $751.0M | $805.0M | $867.0M | $661.0M | $641.0M | $632.8M |
| Operating income | $5.25B | $4.63B | $4.38B | $4.16B | $3.51B | $1.14B | $1.78B | $2.18B |
| EBITDA | $6.23B | $7.21B | $7.19B | $6.95B | $3.10B | $2.73B | $3.14B | $3.30B |
| Net income | $2.03B | $3.03B | $2.82B | $2.82B | $2.12B | −$594.0M | $471.0M | $1.26B |
| Net margin | 6.0% | 8.6% | 7.8% | 7.5% | 5.2% | -2.7% | 2.2% | 5.5% |
| EPS (diluted) | 3.63 | 5.43 | 5.06 | 5.05 | 3.77 | -1.05 | 0.84 | 2.25 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $23.5B | $3.49 | $3.44–$3.53 | 10 |
| 2027 | $24.7B | $3.82 | $3.76–$3.86 | 5 |
| 2028 | $26.0B | $4.21 | $4.15–$4.25 | 7 |
| 2029 | $27.4B | $4.72 | $4.65–$4.77 | 10 |
Forward consensus · source: Financial Modeling Prep
FRESENIUS SE & CO
No one on the platform currently holds FSNUF.
No tracked institution reports a position in FSNUF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2026-05-26 | $1.0500 | 2026-05-27 |
| 2025-05-27 | $1.0000 | 2025-05-28 |
| Execution date | Ratio |
|---|---|
| 2007-02-02 | 3-for-1 |
No one on the platform has traded FSNUF yet.
| +0.00% |
| $1576 |
| — |
| OTSKYOtsuka Holdings Co., Ltd. | $33.48 | -1.70% | $35.3B | — |
| RSMDFResMed Inc. | $16.72 | +0.00% | $28.8B | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at 71.5× earnings vs its 20.8× historical median P/E.
Fair value ≈ $15.80 · price $54.35 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.